Merck and Eisai provide update on Phase 3 LEAP-002 trial evaluating KEYTRUDA

The safety profile of KEYTRUDA plus LENVIMA was consistent with previously reported data on the combination.

Statement from Krsnaa Diagnostics on IT survey

The news report stating Krsnaa Diagnostics has accepted Rs 100 crores of undisclosed income is incorrect and baseless.

Urinary incontinence 2nd biggest reason for limited mobility in elderly: Survey

72.5% elderly feel their generation used to spend more time with their elders, 52.4% feel lonely, shows PAN Health’s Liberty in Life of Older People 2022 survey

Merck updates on Phase 3 Keynote-412 trial in advanced head and neck squamous cell carcinoma

50%+ patients delay cataract surgeries in India: Survey

73% have cited fears like losing eyesight, painful procedure or long recovery period when it comes to cataract surgeries

R&D key for the growth of nation: Dr. Mandaviya

The Minister lauded and extended his gratitude to the scientists who developed the vaccine during pandemic.

Syntegra partners with TMA Precision to reduce the diagnostic odyssey for rare disease with synthetic data-enabled tools

TMA will leverage Syntegra's synthetic data engine to accelerate the building of predictive diagnostic algorithms

FDA accepts application for Merck’s Keytruda as adjuvant therapy for Stage IB-IIIA lung cancer

Acceptance based on results from the phase 3 KEYNOTE-091 trial

CerTest Biotec and BD collaborates for molecular diagnostic test for Monkeypox

CerTest Biotec uses the BD MAX molecular diagnostic system open system reagent suite to develop RT-PCR detection kit

Gilead Sciences appoints Stacey Ma as EVP, Pharmaceutical Development and Manufacturing

Taiyin Yang, PhD, Executive Vice President, Pharmaceutical Development and Manufacturing to Retire After 29 Years at Gilead